The agreement will cover the commercial rights to  metoprolol tartrate and metoprolol succinate respectively and associated Logimax fixed-dose combination (metoprolol succinate and felodipine) treatments in Europe. Recordati will pay AstraZeneca $300 million upon completion of the agreement. AstraZeneca will manufacture and supply the medicines under a supply agreement. The drug product is a beta-blocker indicated for the control of a range of conditions including hypertension, angina pectoris, disturbances of cardiac rhythm, maintenance treatment after myocardial infarction and functional heart disorders with palpitations.


Please enter your comment!
Please enter your name here